Psych Vivas · Addiction psychiatry — substance use disorders
Opioid substitution therapy and withdrawal — structured clinical viva
Fellowship viva on methadone–buprenorphine transfer, QTc, precipitated withdrawal, naltrexone timing, and retention mortality.
On this page & tools
Target exams
Interpretation
Reveal interpretation
This is a transfer and risk-communication viva, not an automatic switch. Methadone 100 mg is a substantial full-agonist dose; jumping to buprenorphine without adequate withdrawal precipitates severe withdrawal. One missed dose plus remote heroin use does not equal a safe naltrexone start this week.[2][4]
QTc 465 ms needs context (sex-specific cut-offs, electrolytes, symptoms, interacting drugs). Krantz et al. frame systematic QTc screening — borderline values prompt review, dose consideration, and shared decisions, not necessarily panic cessation without a plan.[1]
Buprenorphine transfer usually requires specialist protocol: reduce methadone, wait for objective withdrawal (COWS), then induct carefully. Benefits may include partial-agonist respiratory ceiling and take-home logistics — not zero risk.[4][6]
Naltrexone implant/XR requires completed detox and is not a one-week “cure.” X:BOT highlights induction difficulty versus buprenorphine–naloxone. Implants are jurisdiction-specific.[3]
Frame retention mortality: leaving OAT impulsively for unproven online plans raises overdose risk.[5]
Key points
[1] [2] [3] [4] [5]References
- [1]Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment Ann Intern Med, 2009.PMID 19153406
- [2]Wesson DR, Ling W The Clinical Opiate Withdrawal Scale (COWS) J Psychoactive Drugs, 2003.PMID 12924748
- [3]Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) Lancet, 2018.PMID 29150198
- [4]American Society of Addiction Medicine The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update J Addict Med, 2020.PMID 32511106
- [5]Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment BMJ, 2017.PMID 28446428
- [6]Mattick RP, Breen C, Kimber J, Davoli M Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst Rev, 2014.PMID 24500948